Novel vaccine which is developed based on a modified measles virus shows a promise against the chikungunya virus, reports a new clinical trial study. The findings of the study are published in the journal The Lancet.
The Phase II trial, led by the University of Vienna in Austria, showed that just two injections are enough to provide immunity, regardless of whether these are given at an interval of one or six months.
Chikungunya
Chikungunya is a viral disease spread by mosquito bites; it causes fever, severe joint pain and rash on the body. Chikungunya occurs in Africa, Asia and the Indian sub continent.
Advertisement
‘Chikungunya is an emerging viral disease and a real threat to public health. There is no specific treatment currently which is capable of halting the chikungunya virus. But a novel vaccine shows promise against the virus in a clinical trial.’
Read More..
Tweet it Now
Read More..
The vaccine is injected into the muscle and triggers the production of antibodies in the lymphatic system. If the person is infected with the chikungunya virus, these antibodies are ready to neutralize the virus so that the disease does not take hold.
The results "are very promising in terms of immunogenicity, safety, and tolerability of the vaccine," said Ursula Wiedermann-Schmidt, Professor from the varsity.
![First Antiviral Drug Piperazine For Chikungunya]( "First Antiviral Drug Piperazine For Chikungunya")
Piperazine which is a drug used for deworming can be used as an antiviral agent to treat chikungunya.
The vaccine is a live vaccine based on the measles virus vaccinal strain, which has been genetically modified to express the surface proteins of chikungunya.
Neutralising antibodies are formed after a single vaccination.
Also, it increases or boosts the protective substances or antibodies against measles.
The Phase II trials were conducted over 263 volunteers.
Chikungunya fever is an emerging viral disease, and a substantial threat to public health and the virus is spreading throughout the world particularly in India, Indonesia, Sri Lanka, and Thailand.
Currently, there is no specific treatment capable of halting the chikungunya virus and the associated high fever with severe muscle, limb and joint pain, which can even prove fatal under certain circumstances.
Source: IANS
First Antiviral Drug Piperazine For Chikungunya
Piperazine which is a drug used for deworming can be used as an antiviral agent to treat chikungunya.
Advertisement
The vaccine is a live vaccine based on the measles virus vaccinal strain, which has been genetically modified to express the surface proteins of chikungunya.
Neutralising antibodies are formed after a single vaccination.
Also, it increases or boosts the protective substances or antibodies against measles.
The Phase II trials were conducted over 263 volunteers.
Chikungunya fever is an emerging viral disease, and a substantial threat to public health and the virus is spreading throughout the world particularly in India, Indonesia, Sri Lanka, and Thailand.
Currently, there is no specific treatment capable of halting the chikungunya virus and the associated high fever with severe muscle, limb and joint pain, which can even prove fatal under certain circumstances.
Source: IANS
Combining Drug for Virus and Arthritis Found Effective in Chikungunya
A combination of drugs was found to be effective against the acute phase of chikungunya infection, providing first sign of treatment.
Advertisement
 Mosquitoes Could Infect Humans With Zika and Chikungunya SimultaneouslyMosquitoes are capable of carrying multiple viruses simultaneously and can infect humans in a single bit. | Advertisement
|
Advertisement
Recommended Reading
Latest Tropical Disease News
Mumbai's TechInvention Lifecare and South Korean Eubiologics team up to introduce oral cholera vaccine in India after successful phase III clinical trial.
Scientists have found that the dengue virus has become more severe in India, highlighting the urgent need for vaccines that target the strains found in the country.
It is important to consider malarial infection in cases of acute kidney injury in someone with a travel history from endemic areas to improve treatment outcomes.
Ghana approves the use of the University of Oxford's malaria vaccine, produced by the Serum Institute of India (SII), becoming the first country to adopt the new vaccine.
The dengue virus combines molecules from its RNA with mosquito saliva to foil the human immune system and spread dengue fever and related diseases.